[Skip to Content]
[Skip to Content Landing]
Article
February 17, 1989

HIV-1 Infection Among Intravenous Drug Users in Manhattan, New York City, From 1977 Through 1987

Author Affiliations

From the New York State Division of Substance Abuse Services (Dr Des Jarlais), Narcotic and Drug Research Inc (Dr Friedman and Ms Sotheran), the Beth Israel Medical Center (Drs Novick, Yancovitz, and Mildvan, and Mr Weber), New York City Department of Health (Dr Thomas), Rockefeller University (Dr Kreek), Bellevue Medical Center, New York (Dr Maslansky and Ms Bartelme); Centers for Disease Control, Atlanta (Dr Spira); and the New York University Medical Center, New York (Dr Marmor).

From the New York State Division of Substance Abuse Services (Dr Des Jarlais), Narcotic and Drug Research Inc (Dr Friedman and Ms Sotheran), the Beth Israel Medical Center (Drs Novick, Yancovitz, and Mildvan, and Mr Weber), New York City Department of Health (Dr Thomas), Rockefeller University (Dr Kreek), Bellevue Medical Center, New York (Dr Maslansky and Ms Bartelme); Centers for Disease Control, Atlanta (Dr Spira); and the New York University Medical Center, New York (Dr Marmor).

JAMA. 1989;261(7):1008-1012. doi:10.1001/jama.1989.03420070058030
Abstract

Intravenous drug users are the second largest group to develop the acquired immunodeficiency syndrome, and they are the primary source for heterosexual and perinatal transmission in the United States and Europe. Understanding long-term trends in the spread of human immunodeficiency virus among intravenous drug users is critical to controlling the acquired immunodeficiency syndrome epidemic. Acquired immunodeficiency syndrome surveillance data and seroprevalence studies of drug treatment program entrants are used to trace seroprevalence trends among intravenous drug users in the borough of Manhattan. The virus entered this drug-using group during the mid-1970s and spread rapidly in 1979 through 1983. From 1984 through 1987, the seroprevalence rate stabilized between 55% and 60%—well below hepatitis B seroprevalence rates. This relatively constant rate is attributed to new infections, new seronegative persons beginning drug injection, seropositive persons leaving drug injection, and increasing conscious risk reduction.

(JAMA 1989;261:1008-1012)

×